Document:

Agreement Regarding Academic Clinical Study

	 CONFIDENTIAL TREATMENT REQUESTED 
	 EXHIBIT 10.22 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 OF THE SECURITIES ACT OF 1933 CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN
PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AGREEMENT REGARDING ACADEMIC

 CLINICAL STUDY 
 BETWEEN 
 THE CANCER RESEARCH
INSTITUTE 
 OF CONTRA COSTA 
 AND 
 SOMANTA
LIMITED 
  

 1 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 AGREEMENT REGARDING ACADEMIC CLINICAL STUDY 
 THIS AGREEMENT REGARDING ACADEMIC CLINICAL
STUDY (the “Agreement”) is entered into as of August 18, 2005 (the “Effective Date”) by and between SOMANTA
LIMITED, a corporation organized under the laws of England (“Somanta”), and THE CANCER RESEARCH INSTITUTE OF
CONTRA COSTA, a non-profit research institution (“CRICC”), each individually referred to in this Agreement as a “Party” and both collectively as the
“Parties”. 
 RECITALS 
 WHEREAS, Somanta is the sublicensee under that certain Patent and Know-how Exclusive Sublicense Agreement dated as of even date herewith with Immunodex, Inc.
(“Immunodex”), licensee of CRICC, related to certain patents covering the antibody know as HuBrE-3 and certain patents covering the antibody known as HuMc-3; 
 WHEREAS, CRICC desires to continue to coordinate a Phase I-II clinical trial with escalating dose protocol of 90Y-HuBrE-3 and/or
protocol combining 90Y-HuBrE-3 and Xeloda to be conducted within the United States of America (the “Clinical Trial”); and 
 WHEREAS, Somanta desires to provide funding to CRICC to enable the Clinical Trial, subject to the terms and conditions set forth herein. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of
the mutual covenants and promises set forth herein, the parties hereby agree as follows: 
 1. Selection of Clinical Trial Site.
CRICC shall identify an appropriate institution (or institutions) that has the experience, facilities and resources to undertake the Clinical Trial. CRICC shall enter into an agreement with each applicable institution which shall, among other
things, require such institution to undertake the Clinical Trial in accordance with generally accepted good clinical practices that are consistent with the Clinical Trial’s approved protocol. Before any patient is treated in the Clinical Trial,
the institution conducting the Clinical Trial shall have received approval from its institutional review board and any relevant human subject protection committee. 
 2. Provision of Materials. CRICC, or immunodex, shall provide [CONFIDENTIAL TREATMENT REQUESTED] HuBrE-3 for the Clinical Trial to each applicable institution in accordance with any applicable
regulations or consents of the U.S. Food and Drug Administration. 
 3. Payment Schedule. In connection with the conduct of the
Clinical Trial and in consideration for the services to be performed by CRICC in connection therewith, Somanta will make payments to CRICC in accordance with this Section 3. At such time as Somanta shall have received a completed case reporting
form for a patient in accordance with the Clinical Trial protocol, Somanta will (i) reimburse CRICC in an amount equal to the amount to be paid by CRICC to the relevant institution conducting the Clinical Trial with respect to such patient,
plus 

  

 2 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
(ii) [CONFIDENTIAL TREATMENT REQUESTED]. The parties acknowledge and agree that CRICC is currently obligated to pay New York University
[CONFIDENTIAL TREATMENT REQUESTED] per patient in connection with the Clinical Trial. To the extent CRICC engages additional institutions in connection with conduct of the Clinical Trial, CRICC shall use reasonable efforts to negotiate a
price to be paid by CRICC for each patient included in the Clinical Trial at such institution shall not exceed the amount to be paid to the University of New York per patient. 
 4. Supervision of Trial. The Parties acknowledge and agree that the Clinical Trial shall be supervised by a committee comprised of Drs.
Jerry Peterson and Roberto Ceriani and each applicable principal investigator at the Clinical Trial site institution(s) (the “Committee”). Drs. Peterson and Ceriani, to the extent permitted by the clinical trial site, shall
have direct access to all data produced in and related to the Clinical Trial and the ability to interact with all scientific and clinical members of the Clinical Trial at each institution in addition to each applicable principal investigator. In
addition, CRICC or the Clinical Trial site will file, or cause to be filed, any and all reports related to the Clinical Trial as required by applicable law (the “FDA Reports”). 
 In view of Drs. Peterson’s and Ceriani’s expertise in the area of the conduct of clinical trials and longstanding involvement in the research
and clinical work that has lead to the Clinical Trial, and to avoid any lack of coordination or confusion, Somanta shall, if it receives any inquiry from a clinical site or clinical investigator participating in the Clinical Trial regarding a
regulatory, clinical or technical matter, refer such person to one of Drs. Peterson and Ceriani. Drs. Peterson and Ceriani will keep Somanta informed of the resolution of such inquiries. 
 5. Confidentiality. 
 (a)
Confidentiality Obligation. During the term of this Agreement and for a period of five (5) years thereafter, the parties hereto will maintain all Confidential Information (as defined below) as confidential and will not disclose any
Confidential Information or use any Confidential Information for any purpose, except (i) as expressly authorized by this Agreement, (ii) as required by law, rule, regulation or court order (provided that the Disclosing Party (as defined
below) uses reasonable efforts to obtain a protective order or to seek confidential treatment of any such information required to be disclosed), or (iii) to its employees, agents, consultants and other representatives who require access to such
information to accomplish the purposes of this Agreement so long as such persons are under an obligation of confidentiality no less stringent than as set forth herein. Notwithstanding anything to the contrary herein, (A) CRICC acknowledges and
agrees that Somanta may disclose Confidential Information to (i) the U.S. Food and Drug Administration (“FDA”) and/or corresponding foreign regulatory authorities in connection with the regulatory filings related to the
development of Somanta products, and (ii) potential investors of Somanta in connection with such investors’ due diligence investigation of Somanta; and (B) Somanta acknowledges and agrees that CRICC may disclose Confidential
Information to the FDA in connection with the filing of the FDA Reports. 
 (b) Definition. For purpose of this Agreement,
“Confidential Information” means all information provided by or on behalf of one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) in connection with the
Clinical Trial and all data and 

  

 3 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
information developed pursuant to the Clinical Trial, whether in oral, written, graphic or electronic form. Notwithstanding the foregoing, Confidential
Information will not include any information which the Receiving Party can prove by competent written evidence: (i) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available;
(ii) is known by the Receiving Party at the time of receiving such information; (iii) is hereafter furnished to the Receiving Party by a third party, as a matter of right and without restriction on disclosure; (iv) is the subject of a
written permission to disclose provided by Disclosing Party, or (v) is published in accordance with Section 6. The Receiving Party may disclose the Confidential Information to comply with applicable governmental regulations, provided that
if such disclosure is required, Receiving Party will, to the extent practicable, give reasonable advance notice to Disclosing Party of such disclosure requirement and will use its best efforts to secure confidential treatment of such information
required to be disclosed. 
 6. PUBLICATIONS. In the event that either Party and/or their respective employees, agents,
consultants or other representatives, or those of a clinical site or clinical investigator participating in the Clinical Trial, wish to make a publication (including any oral disclosure made without obligation of confidentiality) relating to the
Clinical Trial such Party will deliver to the other Party a copy of the proposed written publication or an outline of such oral disclosure at least thirty (30) days prior to submission for publication or presentation, as applicable. Such other
Party will have the right (a) to propose modifications to the publication for protection of Confidential Information or other reasons (however, to avoid any doubt, beyond the delay time period set forth herein to enable patent filing as set
forth below, clinical investigators, including without limitation Drs. Peterson and Ceriani, shall not be prohibited from publishing data, results and information from the Clinical Trial), and (b) to request a delay in publication in order to
protect patentable information. If such other Party requests such a delay, the Party desiring to publish will delay submission or presentation of the publication for a period of sixty (60) days to enable patent applications protecting such
other Party’s rights in such information to be filed. Upon the expiration of thirty (30) days from delivery of the proposed written publication or the outline of any oral disclosure, as applicable, to such other Party the Party desiring to
publish will be free to proceed with the written publication or the oral presentation, respectively, unless such other Party has requested the delay described above. In no event shall a Party publish any Confidential Information in such proposed
publication without the other Party’s prior written consent. In addition, CRICC shall require each institution conducting the Clinical Trial to enter into covenants with respect to Confidential Information and publications substantially similar
to those contained in Sections 5 and 6 this Agreement. 
 7. Rights to Data. 
 (a) No License. Except as expressly set forth in this Agreement, nothing herein shall be construed as a license, assignment or any other right to
practice or use any invention or other intellectual property of any Party to this Agreement. 
 (b) Results and Data. Somanta shall be
provided with, and shall have the right to access and use, all data collected or generated in the course of conducting the Clinical Trial, including, without limitation, records, reports, specimens, and other work product generated by or on behalf
of any principal investigator in the course of performing the Clinical Trial, whether in written, graphic or electronic form or contained in any computer database or in any computer readable form (“Data”). CRICC agrees to
attempt to require the principal investigator to ensure the accuracy, completeness, legibility and timeliness of all Data provided. 
  

 4 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 8. INDEMNIFICATION. 
 (a) By CRICC. CRICC will defend, indemnify and hold harmless Somanta and its directors, officers, agents, consultants and employees, from and
against all claims, demands, actions, suits and proceedings that may be brought or instituted by a third party (“Claims”), and all judgments, damages, losses, liabilities, costs and expenses resulting therefrom, resulting
directly from (i) the gross negligence, recklessness or willful misconduct of any CRICC Indemnitee (defined in Section 8(b)) or (ii) any failure by any CRICC Indemnitee to perform his or her obligations under this Agreement in
compliance with applicable laws (including without limitation governmental rules and regulations promulgated thereunder). 
 (b) By
Somanta. Somanta will defend, indemnify and hold harmless CRICC, Immunodex and their trustees, directors, officers, agents, consultants and employees (collectively, the “CRICC Indemnitees”) as well as each institution at
which the Clinical Trial takes place (including, without limitation, their directors, officers, agents, consultants and employees (“Site Indemnitees”), from and against all Claims, and all judgments, damages, losses,
liabilities, costs and expenses (including without limitation attorneys’ fees) resulting therefrom, arising out of or resulting from the Clinical Trial, except solely to the extent resulting directly from (i) the gross negligence,
recklessness or willful misconduct of any CRICC Indemnitee, (ii) any failure by any CRICC Indemnitee to perform his or her obligations under this Agreement in compliance with applicable laws, rules or regulations, or solely with respect to
indemnification of the Site Indemnitees (iii) (a) the gross negligence, recklessness or willful misconduct of any Site Indemnitee, or (b) any failure by any Site Indemnitee to perform his or her obligations under the written agreement
contracting for such obligations, in compliance with applicable laws, rules or regulations. 
 (c) Procedure. In the event either
Party seeks indemnification under this Section 8, it will inform the other Party of a Claim as soon as reasonably practicable after it receives notice of the claim, will permit the other Party to assume direction and control of the defense of
the Claim (at the indemnifying Party’s expense) (including the right to settle the Claim solely for monetary consideration), and will cooperate as requested (at the expense of the other Party) in the defense of the Claim. Any failure to
promptly provide notice as required in the foregoing sentence shall only relieve the indemnifying Party of its indemnification obligation to the extent the delay prejudices defense of the Claim. 
 9. REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY.

 (a) Authority. Each Party represents and warrants that it has full power and authority to enter into this Agreement and to
perform all of its obligations hereunder. 
 (b) Due Authorization. Each Party hereby represents and warrants that such Party is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder. 
  

 5 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 (c) Binding Agreement. Each Party hereby represents and warrants that this Agreement is a
legal and valid obligation binding upon it and is enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a Party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over it. 
 (d) Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER
PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 10. TERM AND TERMINATION. 
 (a) Term. The term of
this Agreement will commence on the Effective Date and will expire upon completion of the Clinical Trial, unless terminated earlier as provided herein or extended by mutual written agreement of the parties. “Completion of the Clinical
Trial” for those purposes will be deemed to occur the moment all data from the Clinical Sites has been received, reviewed, and submitted by CRICC and approved by Somanta and the final/closure report is filed with the FDA. 
 (b) Termination. This Agreement may be terminated by either Party with thirty (30) days advance written notice upon material breach of this
Agreement by the other Party, unless such breach is cured within such thirty (30) day period. This Agreement may be terminate by the mutual agreement of the Parties. This Agreement will terminate automatically if: (i) at least ten
(10) patients participating in the Clinical Trial are not dosed within twenty-four (24) months after the date of this Agreement on the date that is twenty-four (24) months after the date of this Agreement, or (ii) Somanta becomes
obligated to make payments to Immunodex pursuant to Section 8.4.2(f) of the Patent and Know-how Exclusive Sublicense Agreement of even date herewith between Somanta and Immunodex (the “Sublicense Agreement”) on the date such
obligation arises, or (iii) if the Sublicense Agreement is terminated in its entirety or as to BrE-3 and Somanta is not obligated to make payments to Immunodex pursuant to Section 8.4.2(f) of the Sublicense Agreement pursuant to the terms
of Section 8.4.2(f) of the Sublicense Agreement (i.e., Somanta has already paid for at least ten (10) patients pursuant to this Agreement) on the date of such termination of the Sublicense Agreement or portion thereof. 
 (c) Survival Upon Termination. Expiration or termination of this Agreement will not relieve the parties of any obligation accruing prior to such
expiration or termination. Sections 5, 6, 7, 8, 9, 10(c) and 11 will survive termination of this Agreement. 
 11.
MISCELLANEOUS 
 (a) Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or
obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that Somanta may assign this Agreement and its rights and obligations hereunder without
such consent to the 

  

 6 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
extent it has the right to assign the Patent and Know-how Exclusive Sublicense Agreement of even date herewith between it and Immunodex, solely to its
assignee of such license agreement. The rights and obligations of the parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this
Agreement will be void. 
 (b) Governing Law. This Agreement will be governed by, and construed and enforced in accordance with, the
laws of the State of California, as such laws apply to agreements between California residents performed entirely within the State of California. 
 (c) Waiver. Except as specifically provided for herein, the waiver from time to time by either Party of any right or failure to exercise any remedy will not operate or be construed as a continuing waiver of the same right or remedy
or of any other of such Party’s rights or remedies provided under this Agreement. 
 (d) Severability. In case any provision of
this Agreement will be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby. 
 (e) Entire Agreement; Amendment. This Agreement sets forth all of the agreements and understandings between the parties hereto with respect to the
subject matter hereof, and supersedes and terminates all prior agreements and understandings between the parties with respect to the subject matter hereof, including, without limitation that certain Agreement between Somantis and the Cancer Research
Institute of Contra Costa (CRICC) for Conduction of Academic Clinical Trial with 90Y-HuBrE3, and 90Y-HuBrE3 and Chemotherapy dated October 13, 2003 between Somantis Limited and the Cancer Research Institute of Contra Costa, as amended or
modified to date. There are no agreements or understandings with respect to the subject matter hereof, either oral or written, between the parties other than as set forth herein. Except as expressly set forth in this Agreement, no subsequent
amendment, modification or addition to this Agreement will be binding upon the parties hereto unless reduced to writing and signed by the respective authorized officers of each Party. To avoid any doubt, this Agreement in no way amends or supersedes
the Patent and Know-how Exclusive Sublicense Agreement of even date herewith between Somanta and Immunodex. 
 (f) Independent
Contractors. It is expressly agreed that the parties will be independent contractors and that the relationship between the parties will not constitute a partnership, joint venture or agency of any kind. Neither Party will have the authority to
make any statements, representations or commitments of any kind, or to take any action, which will be binding on the other Party, without the prior written consent of the other Party. 
  

 7 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 (g) Notice. All notices and other communications provided for hereunder will be in writing and
will be mailed by first-class, registered or certified mail, postage paid, or delivered personally, by overnight delivery service or by facsimile, with confirmation of receipt, addressed as follows: 
  

			
	If to Somanta:	  	Somanta Incorporated
		  	10 Old Course Drive
		  	Newport Beach, CA 92660
		  	Attention: Terrance Bruggeman
		  	Facsimile: 949-706-3698
		
	If to CRICC:	  	Cancer Research Institute of Contra Costa, New York Office
		  	[CONFIDENTIAL TREATMENT REQUESTED]

 Either Party may by like notice specify or change an address to which notices and communications
will thereafter be sent. Notices sent by facsimile will be effective upon confirmation of receipt, notices sent by mail or overnight delivery service will be effective upon receipt, and notices given personally will be effective when delivered.

 (h) Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist
in locating and reading the several Sections hereof. 
 (i) Counterparts. This Agreement may be executed in two or more counterparts,
by facsimile, or both, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
  

 8 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 IN WITNESS WHEREOF, the parties have executed
this Agreement as of the Effective Date. 
  

									
	SOMANTA LIMITED	 		 	THE CANCER RESEARCH INSTITUTE OF CONTRA COSTA
					
	By:	 	 /s/ Terrance J. Bruggeman
	 		 	By:	 	 /s/ Jerry A. Peterson

	Name:	 	 Terrance J. Bruggeman
	 		 	Name:	 	 Jerry A. Peterson

	Title:	 	 Chairman
	 		 	Title:	 	 Chief Executive OfficerOveradvance Letter Agreement

 Exhibit 10.1 
 July 13, 2006 
 Accentia Biopharmaceuticals, Inc. 
 The Analytica Group, Inc. 
 TEAMM Pharmaceuticals, Inc. 
 324 South Hyde Park Ave., Suite 350 
 Tampa, Florida 33606 
 Attention: Chief Financial Officer 
 Re: Overadvance Side Letter 
 Reference is hereby made to that certain Amended and Restated Security Agreement dated as of April 29, 2005, and amended and restated as of
February 13, 2006, by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (“Parent”), The Analytica Group, Inc., a Florida corporation (“Analytica”), TEAMM Pharmaceuticals, Inc., a Florida
corporation by way of joinder dated as of the date hereof (“Teamm” and, together with Analytica and Parent, the “Companies” and, each a “Company”) and Laurus Master Fund, Ltd.
(“Laurus”) (as amended, modified and/or supplemented from time to time, the “Security Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed them in the Security Agreement.
Reference is made to the letter agreement, dated as of December 29, 2005, by and between the Parent, Analytica, The Francis E. O’Donnell, Gr. Irrevocable Trust No. 1 and Laurus (the “Existing Overadvance Waiver”),
pursuant to the terms of which Laurus agreed with the Parent and Analytica to provide an Overadvance in the maximum amount of $2,500,000 through the period commencing on December 29, 2005 and continuing through July 1, 2006 (the
“Existing Overadvance”). In consideration of the agreements set forth below, the receipt and sufficiency of which is hereby acknowledged, notwithstanding the terms of the Existing Overadvance Waiver, the parties hereto each hereby
acknowledge that the Existing Overadvance shall be repaid in full on the date hereof and that, from and after the date hereof, the Existing Overadvance Waiver shall be of no further force or effect. 
 Subject to satisfaction of the Overadvance Conditions (as defined below), Laurus is hereby notifying the Companies of its decision to again exercise the
discretion granted to it pursuant to Section 2(a)(ii) of the Security Agreement to make Loans to the Companies during the Period (as defined below) in excess of the Formula Amount on the date hereof (the “Overadvances”).
Subject to satisfaction of the Overadvance Conditions, the aggregate principal amount of the Overadvances as of the date hereof shall be $7,500,000 and shall at no time hereafter exceed the Maximum Overadvance Limit (as defined below) .
Notwithstanding anything herein to the contrary, the Maximum Overadvance Limit shall at no time be greater 

 than the remainder of (x) $20,000,000 less (y) the principal amount of all Obligations (other than the
Overadvance) outstanding at such time (and shall be reduced as and when necessary to comply with the foregoing).. 
 In connection with
making the Overadvances, during and in respect of the period commencing on the date hereof through and including the January 1, 2007 (or earlier to the extent that the Overadvances are earlier permanently repaid in full per the terms of the
proviso set forth at the end of this sentence) (the “Period”), Laurus hereby waives compliance with Section 3 of the Security Agreement, but solely as such provision relates to the immediate repayment requirement for
Overadvances. Laurus further agrees that solely for such Period (but not thereafter), (i) the incurrence and existence of the Overadvances in itself shall not trigger an Event of Default under Section 19(a) of the Security Agreement and
(ii) notwithstanding anything to the contrary set forth in Section 5(b)(ii) of the Security Agreement, during the Period, the rate of interest applicable to such Overadvances shall be the “prime rate” published in The Wall
Street Journal from time to time (the “Prime Rate”), plus two percent (2%) (collectively, the “Overadvance Rate”). Interest shall be (i) calculated on the basis of a 360 day year, and (ii) payable
monthly, in arrears, commencing on August 1, 2006 on the first business day of each consecutive calendar month thereafter through and including the expiration of the Period, whether by acceleration or otherwise. All other terms and provisions
of the Security Agreement and the Ancillary Agreements shall remain in full force and effect. For the avoidance of doubt, all proceeds applied by any Company in repayment of its obligations to Laurus hereunder and under the Security Agreement and
the Ancillary Agreements shall be first applied as a repayment of the Overadvances unless otherwise agreed by Laurus. Once repaid, Overadvances may be reborrowed during the Period provided that the aggregate amount of all outstanding Overadvances
shall not at any time exceed the Maximum Overadvance Limit then in effect. 
 The Companies hereby each acknowledge and agree that
Laurus’ obligation to fund the Funded Overadvance on the date hereof and each permitted reborrowing thereof after the date hereof (subject to the Maximum Overadvance Limit) shall, at the time of such making of such Funded Overadvance or
reborrowing, and immediately after giving effect thereto, be subject to the satisfaction of the following conditions (the “Overadvance Conditions”): (i) no Event of Default shall exist and be continuing as of such date;
(ii) all representations, warranties and covenants made by the Companies in connection with the Security Agreement and the Ancillary Agreements shall be true, correct and complete as of such date; and (iii) the Companies and their
respective Subsidiaries shall, within thirty (30) days of the date hereof have taken all action necessary to grant Laurus “control” over all of the Companies’ and their respective Subsidiaries’ Deposit Accounts (the
“Control Accounts”), with any agreements establishing “control” to be in form and substance satisfactory to Laurus. “Control” over such Control Accounts shall be released upon the indefeasible repayment in full
and termination of the Overadvance (together with all accrued interest and fees which remain unpaid in respect thereof). 
 The Companies
hereby agree and acknowledge that they shall, on a joint and several basis: (x) permanently and immediately repay in full all amounts outstanding under the Overadvances upon expiration of the Period together with accrued interest and fees which
remain unpaid in respect thereof and (y) immediately repay all amounts outstanding under the Overadvances which are at any time in excess of the Maximum Overadvance Limit during the 
  

 2 

 Period, together with accrued interest and fees which remain unpaid in respect thereof. The failure to make any required
repayment of the Overadvances shall give rise to an immediate Event of Default. The “Maximum Overadvance Limit” shall initially be $7,500,000 and shall be permanently reduced (but not below $0) (x) by an amount equal and
limited to $2,500,000 upon the earlier to occur of July 31, 2006 and the date upon which the Companies first borrow funds from Laurus on the basis of the Eligible Accounts of Teamm and (y) by the amount of the net proceeds (as determined
by Laurus in its sole discretion) of a Teamm Transaction (as defined below). 
 The Companies further acknowledge and agree that (x) the
proceeds of the Overadvances shall be used to repay in full all outstanding obligations owing to Harbinger Mezzanine Partners, LP and its affiliates (collectively, “Harbinger”) and that as a result of such repayment no further
obligations shall be owing by the Parent or any of its Subsidiaries to Harbinger, (y) all guarantees and security interests (and all other interests and obligations related thereto) granted by the Parent or any of its Subsidiaries for the
benefit of Harbinger or any of its affiliates shall be terminated (and evidence of same shall be provided to Laurus and be satisfactory to Laurus in its sole discretion) and Laurus shall have a first priority security interest over all assets and
equity of Teamm (and the Companies will be permitted to include the Eligible Accounts and Eligible Inventory of Teamm in the borrowing base under the Security Agreement pursuant to the terms conditions set forth in the Security Agreement and the
Ancillary Agreements (including, without limitation, the Joinder Agreement, dated as of the date hereof by and between Teamm and Laurus)) and (z) during any time while Section 19(k) of the Security Agreement, Section 5(a) of the Stock
Pledge Agreement, dated as of April 29, 2005, and amended and restated as of April 25, 2006 among the Companies and Laurus (as amended, modified or supplemented from time to time, the “Stock Pledge Agreement”) and/or
Section 3(g) of the Master Security Agreement, dated as of April 29, 2005 among the Companies and Laurus (as amended, modified or supplemented from time to time, the “Master Security Agreement”) continues to remain in
effect, any sale of the Parent’s equity interest in Teamm, or any sale by Teamm of any of its assets (other than inventory in the ordinary course of business or obsolete and worn-out equipment or equipment no longer necessary for its ongoing
needs, having an aggregate fair market value of not more than $100,000, subject to further conditions) (either being, a “Teamm Transaction”), will be subject to the prior written consent of Laurus pursuant to the terms of said
Security Agreement, Stock Pledge Agreement and Master Security Agreement, and consistent with the terms of said Security Agreement, Stock Pledge Agreement and Master Security Agreement, the Parent and Teamm each acknowledge that Laurus may make such
consent conditional on the repayment of all or a portion of the Obligations using 100% of the net proceeds (as determined by Laurus in its sole discretion) of such Teamm Transaction. 
 In consideration of the foregoing, the receipt and sufficiency of which is hereby acknowledged, the Companies shall, on the date hereof, pay to Laurus
Capital Management, LLC, the investment advisor of Laurus (“LCM”), a non-refundable servicing payment in an amount equal to $175,000. The foregoing payment is referred to herein as the “Servicing Payment.” The parties
acknowledge that the Servicing Payment is a reasonable estimate of the expenses that LCM will incur in monitoring and servicing the Overadvance, and the Servicing Payment is intended to enable LCM to defray such expenses. Such payment shall be
deemed fully earned on the date hereof and shall not be subject to rebate or proration for any reason. In further consideration of the foregoing, the receipt and sufficiency of which is hereby 
  

 3 

 acknowledged, the Parent shall issue and transfer to Laurus 100,000 duly authorized and validly issued shares of Common
Stock of the Parent, each with a par value of $0.001 per share and each subject to no liens, claims or encumbrances (the “Additional Shares”). With respect to the acquisition of the Additional Shares, Laurus hereby represents,
warrants, and agrees that (i) the Additional Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act of 1933, as amended (the “Securities Act”), (ii) Laurus is an
“accredited investor” within the meaning of Regulation D under the Securities Act, (iii) Laurus has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision
with respect to the Additional Shares and that Laurus has had an opportunity to ask questions and receive answers from the Parent regarding the Parent’s and its subsidiaries’ business, management and financial affairs, (iv) Laurus has
substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Parent so that it is capable of evaluating the merits and risks of its investment in the Additional Shares and has the
capacity to protect its own interests, (v) Laurus must bear the economic risk of an investment in the Additional Shares until the Additional Shares are sold pursuant to an effective registration statement under the Securities Act or an
exemption from registration is available with respect to such sale, and (vi) Laurus is acquiring the Additional Shares for its own account for investment only, and not as a nominee or agent and not with a view towards or for resale in
connection with their distribution. 
 The Parent further agrees that if at any time after the date hereof there is not an effective
Registration Statement covering all of the Additional Shares issued hereunder and the Parent shall determine to prepare and file with the Securities and Exchange Commission a registration statement relating to an offering for its own account or the
account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection
with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Parent shall send to Laurus written notice of such determination and, if within fifteen
(15) days after receipt of such notice, Laurus shall so request in writing, the Parent shall include in such registration statement all or any part of such Additional Shares Laurus requests to be registered, to the extent the Company may do so
without violating registration rights of others which exist as of the date of this Overadvance Side Letter, subject to customary underwriter cutbacks applicable to all holders of registration rights and subject to obtaining any required consent of
any selling stockholder(s) to such inclusion under such registration statement. 
 The Parent understands that it has an affirmative
obligation to make prompt public disclosure of material agreements and material amendments to such agreements. It is the Parent’s determination that this letter and the terms and provisions of this letter, (collectively, the
“Information”) are material and will be disclosed in an 8-K filing to be filed by the Parent within four (4) days of the date hereof and in the form otherwise prescribed by the SEC. The Parent has had an opportunity to consult
with counsel concerning this determination. 
 This letter may not be amended or waived except by an instrument in writing signed by each of
the Companies and Laurus. This letter may be executed in any number of counterparts, each of which shall be an original and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this letter by
facsimile transmission shall 
  

 4 

 be effective as delivery of a manually executed counterpart hereof or thereof, as the case may be. THIS LETTER SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. This letter sets forth the entire agreement between the parties hereto as to the matters set forth herein and supersede all prior communications, written or oral, with
respect to the matters herein. 
 The Companies hereby represent and warrant to Laurus that the transaction contemplated by or referred to in
this letter (including the repayment of the Overadvance and the repayment of any portion of the Obligations as a condition to a TEAMM Transaction) will not violate or constitute a breach under any provision of the Securities Purchase Agreement,
dated May 15, 2006, among Parent and the persons identified as “Buyers” therein (the “Securities Purchase Agreement”), including without limitation Section 4(n) of the Securities Purchase Agreement. Furthermore, the
Companies hereby agree to jointly and severally indemnify, defend, and hold harmless Laurus and its officers, directors, affiliates, and employees from and against and all damages, liabilities, expenses, costs, and fees (including reasonable
attorneys’ fees) resulting from any claim by a third party against Laurus arising under or related to any provision of the Securities Purchase Agreement, including Section 4(n) thereof. 
 This Overadvance Side Letter shall for all purposes be deemed to be an Ancillary Agreement. 
 If the foregoing meets with the Companies’ approval please signify the Companies’ acceptance of the terms hereof by signing below. 

 

			
	LAURUS MASTER FUND, LTD.
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Director

  

 5 

 AGREED AND ACCEPTED ON THE DATE HEREOF: 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Alan M. Pearce

	Name:	 	Alan M. Pearce
	Title:	 	Chief Financial Officer
	
	THE ANALYTICA GROUP, INC.
		
	By:	 	 /s/ Steve Arikian

	Name:	 	Steve Arikian
	Title:	 	Chairman & CEO
	
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty

	Name:	 	James A. McNulty
	Title:	 	Treasurer

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]